Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition

Abstract

Insights

Signal transducer and activator of transcription 3 (STAT3) activity may predict skin side effects from the mTOR inhibitor everolimus. Inhibiting STAT3 enhanced everolimus

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Mammalian target of rapamycin (mTOR) inhibitors can cause skin issues.
  • Everolimus, an mTOR inhibitor, is linked to dermatological adverse events.
  • The role of signal transducer and activator of transcription 3 (STAT3) in these events is unclear.

Purpose of the Study:

  • To investigate the relationship between STAT3 protein and everolimus-induced dermatological adverse events.
  • To explore STAT3's role in everolimus's effects on keratinocytes.

Main Methods:

  • Utilized WST-8 and western blot analyses to assess everolimus effects on HaCaT cells.
  • Investigated STAT3 activity, cell growth inhibition, and apoptosis.
  • Examined the impact of STAT3 inhibitors (stattic, STA-21) and p38 MAPK inhibitor.

Main Results:

  • STAT3 inhibition enhanced everolimus's cell growth inhibitory effects in HaCaT cells.
  • Everolimus decreased STAT3 phosphorylation at tyrosine 705 in HaCaT cells.
  • STAT3 activation and p38 MAPK inhibition partially resisted everolimus's cytostatic activity.

Conclusions:

  • STAT3 activity may serve as a predictive biomarker for everolimus-induced dermatological toxicity.
  • Understanding STAT3 signaling is crucial for managing everolimus side effects.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K